abstract |
The present invention relates to a pharmaceutical combination comprising a vascular disrupting agent, in particular a tubulin polymerization inhibitor BNC105, and an immunotherapeutic agent, in particular a PD-L1, PD-1, or CTLA-4 antibody, and its use in the treatment of cancer. [Selection figure] None |